Rx Product News

Pharmacy Times, April 2014 Allergy & Asthma, Volume 80, Issue 4

Our round-up of new Rx products.

Marketed by: Zogenix, Inc

Indication: The FDA has approved Zohydro ER (hydrocodone bitartrate), an opioid agonist, for managing severe pain that requires daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. The recommended initial dosage for opioid-naïve and opioid-nontolerant patients is one 10-mg capsule orally every 12 hours. Capsules must be taken whole, 1 at a time, with enough water to ensure complete swallowing immediately after placement in the mouth.

Dosage Form: Extended-release capsules: 10, 15, 20, 30, 40, and 50 mg

For More Information: http://zohydro.com


Marketed by: Sunovion Pharmaceuticals Inc

Indication: The FDA has approved Aptiom (eslicarbazepine acetate), an antiepileptic drug, as an adjunctive treatment for partial-onset seizures. Treatment with Aptiom should be initiated at 400 mg once daily. After 1 week, the dosage may be increased to the recommended maintenance dosage of 800 mg once daily. The maximum dosage of 1200 mg daily should only be initiated after the patient has tolerated 800 mg daily for at least a week.

Dosage Form: Tablets: 200, 400, 600, and 800 mg

For More Information: www.aptiom.com

Novopen Echo

Marketed by: Novo Nordisk

Indication: Novo Nordisk has launched NovoPen Echo, an insulin device designed for children with diabetes. NovoPen Echo is the first and only prefilled pen device in the United States that allows for half-unit dosing in combination with a memory function that records the dose and time passed since the last injection. NovoPen Echo is available for use with NovoLog PenFill cartridges. Patients should eat a meal within 5 to 10 minutes after using NovoLog, a fast-acting insulin analogue.

Dosage Form: Injection pen: adjustable dose of insulin

For More Information: www.novolog.com/InsulinDiabetes/NovoPen.aspx


Marketed by: Pharmacyclics, Inc

Indication: The FDA has approved Imbruvica (ibrutinib), a kinase inhibitor, for the treatment of chronic lymphocytic leukemia in patients who have received at least 1 prior therapy. The recommended dosage is 420 mg orally once daily (three 140-mg capsules once daily). Capsules should be taken orally with a glass of water and should not be opened, broken, or chewed. There are no contraindications for use.

Dosage Form: Capsules: 140 mg

For More Information: www.imbruvica.com